Vaccine · Immune activation · developed by BriaCell Therapeutics
SV-BR-1-GM is an allogeneic breast cancer cell vaccine transfected with the GM-CSF gene. The irradiated cells secrete GM-CSF to stimulate dendritic cell activity and potentiate cytotoxic T-lymphocyte responses against breast cancer. It is studied in metastatic breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06072612 | Phase 3 | Breast Cancer | Recruiting | BCTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Breast CancerBreast Cancer MetastaticBreast NeoplasmEnd Stage CancerMetastatic Breast Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the BCTX page.
See BCTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BCTX catalysts and pipeline →